ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1187

Post-hoc Analysis of Individual Questions from the Australian/Canadian Osteoarthritis Hand Index from a Randomized, Double-blind, Placebo-controlled Trial of Patients with Hand OA

Karin Nicholson1, Edwin Sanchez1, Wendy Wright2, Joel Block3 and Richard Petruschke1, 1Haleon, Warren, NJ, 2Wright & Associates Family Healthcare, Amherst, NH, 3Rush University Medical Center, Chicago, IL

Meeting: ACR Convergence 2023

Keywords: hand, meta-analysis, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1183–1199) Osteoarthritis – Clinical Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Hand osteoarthritis (OA) is a frequently occurring form of OA characterized by symptoms including joint pain, stiffness, and swelling which affect performance of activities of daily living.The Australian/Canadian Osteoarthritis Hand Index (AUSCAN) is a key functional survey for hand OA, consisting of 15 questions organized into three subscales: pain, stiffness, and physical function.While AUSCAN results are typically reported as a total index and/or subscale scores, the individual questions are more granular endpoints which are relevant to patients’ daily activities such as getting dressed, turning doorknobs and faucets, and cooking. The purpose of this post-hoc analysis was to evaluate the scores from the individual AUSCAN questions from an 8-week randomized, double-blind, placebo-controlled trial of diclofenac sodium 1% gel (DSG) vs vehicle in the treatment of hand OA (Altman RD, et al. J Rheumatol 2009;36:1991-9).

Methods: Patients diagnosed with hand OA in the dominant hand were randomly assigned DSG (n = 198) or vehicle (n = 187) and applied 2 g to each hand 4 times daily for 8 weeks. Vehicle was identical to DSG except for the absence of diclofenac sodium.AUSCAN questions were scored using a scale of 0 (no pain/stiffness/difficulty)-100 (extreme pain/stiffness/difficulty) at baseline and at weeks 1, 2, 4, 6 and 8.Mean scores for each question were assessed and compared between treatments at each timepoint using Analysis of Covariance (ANCOVA) with baseline as a covariate in the model and with no multiplicity correction.

Results: DSG demonstrated efficacy with reduction of pain subscale question scores at week 6 by 42%-44% (33%-35% for vehicle), stiffness scores by 42% (30% for vehicle) and physical function subscale scores by 39%-45% (27%-33% for vehicle).Statistically significant differences favoring DSG over vehicle were observed at weeks 4 and 6 (the primary endpoints) in all categories and at week 8 in the stiffness and physical function questions. Specifically, the questions with the greatest separation from vehicle at week 6 involved pain when turning and squeezing objects, stiffness upon wakening, difficulty turning doorknobs and faucets, and difficulty getting dressed, all of which are important components of hand functionality in daily living. Questions that did not reach statistical significance demonstrated a trend favoring DSG.

Conclusion: The results from this analysis show that the individual AUSCAN index question scores for DSG reach statistical significance vs vehicle at week 4 and last through week 8.The DSG scores at week 6 demonstrate a 39%-45% improvement from baseline in performing daily activities including turning objects such as doorknobs and faucets, getting dressed, and cooking compared to 27%-35% reductions from baseline for vehicle. These endpoints may be more meaningful to patients than the subscale scores of pain, stiffness and physical function, and may provide healthcare providers better ways to communicate the benefit of using DSG to treat the symptoms of hand OA.

Supporting image 1

Mean scores for individual AUSCAN questions (0_100 scale)


Disclosures: K. Nicholson: Haleon, 3; E. Sanchez: Haleon, 3; W. Wright: Haleon, 2; J. Block: Haleon, 2; R. Petruschke: Haleon, 3.

To cite this abstract in AMA style:

Nicholson K, Sanchez E, Wright W, Block J, Petruschke R. Post-hoc Analysis of Individual Questions from the Australian/Canadian Osteoarthritis Hand Index from a Randomized, Double-blind, Placebo-controlled Trial of Patients with Hand OA [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/post-hoc-analysis-of-individual-questions-from-the-australian-canadian-osteoarthritis-hand-index-from-a-randomized-double-blind-placebo-controlled-trial-of-patients-with-hand-oa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-hoc-analysis-of-individual-questions-from-the-australian-canadian-osteoarthritis-hand-index-from-a-randomized-double-blind-placebo-controlled-trial-of-patients-with-hand-oa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology